全文获取类型
收费全文 | 274962篇 |
免费 | 8500篇 |
国内免费 | 862篇 |
专业分类
耳鼻咽喉 | 3770篇 |
儿科学 | 9406篇 |
妇产科学 | 7457篇 |
基础医学 | 36315篇 |
口腔科学 | 7530篇 |
临床医学 | 21548篇 |
内科学 | 54716篇 |
皮肤病学 | 6181篇 |
神经病学 | 19013篇 |
特种医学 | 12861篇 |
外国民族医学 | 104篇 |
外科学 | 40498篇 |
综合类 | 1580篇 |
一般理论 | 27篇 |
预防医学 | 23334篇 |
眼科学 | 5537篇 |
药学 | 18776篇 |
2篇 | |
中国医学 | 444篇 |
肿瘤学 | 15225篇 |
出版年
2022年 | 1227篇 |
2021年 | 2419篇 |
2020年 | 1417篇 |
2019年 | 2162篇 |
2018年 | 5995篇 |
2017年 | 5438篇 |
2016年 | 4771篇 |
2015年 | 6609篇 |
2014年 | 6967篇 |
2013年 | 7117篇 |
2012年 | 15226篇 |
2011年 | 10543篇 |
2010年 | 5597篇 |
2009年 | 6874篇 |
2008年 | 7022篇 |
2007年 | 7789篇 |
2006年 | 7750篇 |
2005年 | 15848篇 |
2004年 | 16836篇 |
2003年 | 12365篇 |
2002年 | 7539篇 |
2001年 | 5916篇 |
2000年 | 3370篇 |
1999年 | 7209篇 |
1998年 | 1342篇 |
1992年 | 7485篇 |
1991年 | 7592篇 |
1990年 | 7810篇 |
1989年 | 7345篇 |
1988年 | 6847篇 |
1987年 | 6591篇 |
1986年 | 6318篇 |
1985年 | 5537篇 |
1984年 | 3864篇 |
1983年 | 3152篇 |
1982年 | 1202篇 |
1979年 | 4006篇 |
1978年 | 2530篇 |
1977年 | 1920篇 |
1976年 | 1703篇 |
1975年 | 2619篇 |
1974年 | 3235篇 |
1973年 | 2879篇 |
1972年 | 2876篇 |
1971年 | 2866篇 |
1970年 | 2656篇 |
1969年 | 2557篇 |
1968年 | 2334篇 |
1967年 | 2262篇 |
1966年 | 1981篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Rizzo Manglio Miguel Bluthgen Mara Virginia Recondo Gonzalo Naveira Martin Perfetti Aldo Rizzi Florencia Kuzminin Alejandro Faura Victoria Cerini Matas Videla Alejandro Silva Carlos Lupinacci Lorena Minatta Nicols 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(6):1057-1064
International Journal of Clinical Oncology - Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status... 相似文献
3.
4.
5.
6.
Ingmar Fleps Pierre Guy Stephen J Ferguson Peter A Cripton Benedikt Helgason 《Journal of bone and mineral research》2019,34(10):1837-1850
The majority of hip fractures in the elderly are the result of a fall from standing or from a lower height. Current injury models focus mostly on femur strength while neglecting subject-specific loading. This article presents an injury modeling strategy for hip fractures related to sideways falls that takes subject-specific impact loading into account. Finite element models (FEMs) of the human body were used to predict the experienced load and the femoral strength in a single model. We validated these models for their predicted peak force, effective pelvic stiffness, and fracture status against matching ex vivo sideways fall impacts (n = 11) with a trochanter velocity of 3.1 m/s. Furthermore, they were compared to sideways impacts of volunteers with lower impact velocities that were previously conducted by other groups. Good agreement was found between the ex vivo experiments and the FEMs with respect to peak force (root mean square error [RMSE] = 10.7%, R2 = 0.85) and effective pelvic stiffness (R2 = 0.92, RMSE = 12.9%). The FEMs were predictive of the fracture status for 10 out of 11 specimens. Compared to the volunteer experiments from low height, the FEMs overestimated the peak force by 25% for low BMI subjects and 8% for high BMI subjects. The effective pelvic stiffness values that were derived from the FEMs were comparable to those derived from impacts with volunteers. The force attenuation from the impact surface to the femur ranged between 27% and 54% and was highly dependent on soft tissue thickness (R2 = 0.86). The energy balance in the FEMS showed that at the time of peak force 79% to 93% of the total energy is either kinetic or was transformed to soft tissue deformation. The presented FEMs allow for direct discrimination between fracture and nonfracture outcome for sideways falls and bridge the gap between impact testing with volunteers and impact conditions representative of real life falls. © 2019 American Society for Bone and Mineral Research. 相似文献
7.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
8.
9.
Pierre Tiberghien Xavier de Lamballerie Pascal Morel Pierre Gallian Karine Lacombe Yazdan Yazdanpanah 《Vox sanguinis》2020,115(6):488-494
Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality. 相似文献